Healthcare, Pharma & Life Sciences

Toronto -- Syneos Health experts will lead a free webinar on December 1, 2026, at 11am EST (5pm CET) on how neuroscience sponsors are changing patient identification, endpoint selection and treatment-response assessment across CNS disorders. Xtalks is hosting the session, titled "Neuroscience Development: Are We Measuring What Matters?"

Disease heterogeneity and response variability are pressuring traditional trial design

Alzheimer's disease, Parkinson's disease and psychiatry trials face disease heterogeneity, limited trial accessibility and variable treatment response. These factors are forcing sponsors to reassess how they identify patients, measure treatment effects and make development decisions. Panelists will examine why traditional measures of treatment response are being re-examined and how sponsors are evaluating endpoints that better capture clinically meaningful change.

FOSTER CITY – November 10, 2026 -- OrthoTrophix reported that femoral bone shape stabilized in knees treated with its osteoarthritis candidate TPX-100, while it kept changing in placebo-treated knees, according to two posters presented at ACR Convergence 2026 in Orlando (November 6-11).

MRI analysis links B-score to meniscal pathology

Poster #1581, presented November 9, is a retrospective MRI analysis of a one-year, double-blind Phase 2a study of intra-articular TPX-100 in knee osteoarthritis (KOA). Femoral bone shape, measured by B-score, was significantly associated with baseline meniscal pathology at 6 and 12 months.

In placebo-treated knees, the bone-meniscus link strengthened over time. In TPX-100-treated knees, bone shape stabilized and the link weakened. The company says this suggests TPX-100 may alter the structural course of KOA in patients with high meniscal disease burden.

McLean – November 10, 2026 -- The Association of Organ Procurement Organizations (AOPO) has submitted three additional performance measures to the Partnership for Quality Measurement (PQM) for national endorsement, extending a multi-year push to replace the two unendorsed outcome measures that CMS currently uses to evaluate organ procurement organizations (OPOs).

Three measures target donor care, organ recovery and utilization

The Donor Management Goals (DMG) Bundle Rate assesses the effectiveness of donor care and flags ways to optimize organ function and raise the number of organs available for transplant. The Organs Recovered Per Donor (ORPD) Rate tracks the average number of organs recovered from each deceased donor, whether or not those organs are ultimately transplanted.

Burlingame – November 10, 2026 -- Ember AI's integration with NextGen Enterprise is now available through the NextGen Healthcare Marketplace, giving specialty practices a pre-submission tool to catch coding errors and missed charges, the company announced.

The platform analyzes authorized clinical documentation and encounter data to flag potential coding errors, missed charges, documentation gaps and reimbursement risks before claims are submitted. Ember AI says this reduces preventable denials and eases the administrative load on revenue cycle teams, without disrupting existing workflows.

CEO and co-founder Charlene Wang said specialty practices face pressure from "increasingly complex coding requirements, payer policies and administrative workloads."

Bolingbrook – November 10, 2026 -- Therapy Partners Group (TPG), operator of 24 physical therapy and wellness brands across more than 150 clinics in 7 states, has selected Prompt Health as its long-term technology and business partner, moving every brand onto one AI-powered platform.

TPG consolidates all 24 brands on a single Prompt platform

TPG, a physical therapist-led portfolio company of Shore Capital Partners formed in 2019, said the decision started with its clinicians. The company wanted technology that makes it a better employer while improving operational efficiency and patient experience. CEO Brent Mack, PT, DPT, said the goal is to leave clinicians with "less work following them home."

Changsha – November 10, 2026 -- The 2026 Chinese Congress on Holistic Integrative Oncology (CCHIO) will run from November 12 to 15 in Changsha, Hunan Province, with more than 100 international sessions on cancer prevention, treatment and rehabilitation.

Four organizations back the congress under a collaboration-focused theme

The China Anti-Cancer Association (CACA) hosts the event. The International Association for Holistic Integrative Medicine (IAHIM), the World Association for Integrative Oncology (WAIO) and the Hunan Anti-Cancer Association co-host it. Hunan Cancer Hospital is the organizer.

The theme is "Cancer Control, Winning in Integration." The program centers on collaboration between traditional Chinese and Western medicine, interdisciplinary integration, and care across the full cancer continuum.

New York – November 10, 2026 -- Deerfield Management has designated Amazon Web Services (AWS) a preferred AI provider for the firm and selected portfolio companies, extending generative AI and cloud access across a healthcare investor with more than 190 professionals.

AWS technology flows into Deerfield's R&D and intelligence units

Deerfield Intelligence and Deerfield Discovery and Development (3DC) will receive AWS AI and cloud technology plus technical support. The aim is to scale proprietary healthcare AI products and spread AI capabilities across interested portfolio companies. The collaboration also targets integration of AWS AI services into Deerfield's own research, evaluation and operating processes.

BOSTON – November 10, 2026 -- Aisa Pharma, Inc. reported that its once-daily oral drug AISA-021 (cilnidipine) cut the mean frequency of Raynaud's attacks by 43% from baseline in the Part B crossover phase of the Phase 2 RECONNOITER-1 trial in systemic sclerosis-associated Raynaud's phenomenon (SSc RP). Placebo-treated patients saw a 26% reduction (p=0.028). The company has asked the U.S. Food and Drug Administration (FDA) for a Type C meeting on its development strategy and potential registration pathway, and is preparing a global Phase 3 pivotal study.

Attack-free days rise nearly fourfold from baseline in AISA-021 arm

AISA-021 delivered a placebo-adjusted improvement of more than 155% in the proportion of attack-free days, a nearly fourfold increase from baseline (p=0.013). The drug also significantly shortened attack duration (p=0.02) and improved skin temperature measured by thermography at the proximal interphalangeal joint (p=0.047).

Boston – November 10, 2026 -- HotSpot Therapeutics reported preclinical data showing that its oral IRF5 inhibitor HST-2011 suppressed three disease-driving pathways in systemic lupus erythematosus (SLE) across human cell systems, human whole blood and cynomolgus monkeys. The data were presented in a poster at ACR Convergence 2026.

HST-2011 reduces B cell, interferon and cytokine readouts in three models

In human cellular systems, HST-2011 inhibited plasmablast formation and IgG production. It also potently inhibited type I interferon and proinflammatory cytokine production, including TNF and IL-1β.

In human whole blood stimulated with a TLR agonist, the compound reduced plasmablast, B-cell activation and interferon gene signature scores. mRNA sequencing showed reduced expression of IFNB1, TNF and IL1B.

SARASOTA – November 10, 2026 -- World Precision Instruments (WPI) has launched EVOM Auto ElectroZ, which extends its automated transepithelial/endothelial electrical resistance (TEER) platform with electrochemical impedance spectroscopy (EIS) across frequencies from 2 Hz to 100 kHz. The system is available now.

ElectroZ measures impedance from 2 Hz to 100 kHz in under 20 seconds

Conventional TEER measures resistance across a cell layer at a single frequency of 12.5 Hz. ElectroZ captures both resistive and capacitive properties of living cells in a measurement that often takes less than 20 seconds.

The software automatically calculates four parameters: